NDAORALTABLET
Approved
Oct 2018
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
6
Data completeness
4/8 — Partial
Drug data last refreshed 14h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SEYSARA (sarecycline hydrochloride) is an oral tetracycline-class antibiotic approved in October 2018 for the treatment of moderate acne vulgaris. It is a narrow-spectrum tetracycline designed to target acne-causing bacteria while minimizing disruption to normal microbiota. The drug represents a modern addition to the tetracycline class with improved selectivity.
$0.658MPart D
Peak6.5 years to LOESEYSARA remains in peak commercial phase with modest Part D utilization; brand team size likely stable but not expanding aggressively.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (6)
Comparing Sarecycline and Doxycycline Effects on the Skin and Gut Bacteria in Acne.
Started Apr 2026
30 enrolled
Acne Vulgaris
Patient-reported Outcomes for Sarecycline Effectiveness and Safety (PROSES)
Started Mar 2021
300 enrolled
Acne Vulgaris
Sarecycline Truncal Acne Safety and Efficacy Response
Started Mar 2021
10 enrolled
Acne Vulgaris
A Multi-Center Open-Label Evaluation of the Safety of Sarecycline Tablets in the Treatment of Acne Vulgaris
Started Mar 2015
490 enrolled
Acne Vulgaris
Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne
Started Dec 2014
968 enrolled
Acne Vulgaris
Worked on SEYSARA at Almirall? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.